- Trial phase
- Approved
- Time to market
- Already approved and marketed (US since 2015, EU since 2013). The booster label expansion for ages 10+ is under EMA review with a positive CHMP opinion; European Commission decision expected within 1-2 months.
- Why 4/10
- The next catalyst is the European Commission's decision on the booster label expansion, which typically follows the CHMP positive opinion (received November 13, 2026) within 1-2 months. However, Bexsero is an already-approved, marketed product at a large diversified pharma company (GSK), so this label expansion is a modest commercial event, not a binary approval catalyst.
The CHMP recommended Bexsero's label expansion for a single booster dose on November 13, 2026. The European Commission typically follows CHMP recommendations within 1-2 months, which would be the next catalyst. If approved, this expands the addressable adolescent/young adult booster market in Europe. Separately, Bexsero is being studied for cross-protection against gonorrhea, a potential long-term value driver, but no pivotal readout is scheduled.
Price Chart
Executive Summary
Bexsero is GSK's approved meningococcal group B (MenB) vaccine, first authorized in Europe in 2013 and the US in January 2015. It is a marketed product facing competition from Pfizer's Trumenba and increasingly from GSK's own broader 5-in-1 meningococcal vaccine PENMENVY (approved 2025). On November 13, 2026, GSK announced a positive CHMP opinion recommending a label expansion for a single booster dose in ages 10+, based on Phase IIIb data. The European Commission decision (expected within 1-2 months) is the next catalyst. Bexsero is also being studied for cross-protection against gonorrhea, a potential long-term opportunity. For a large diversified pharma like GSK, Bexsero is one of many products; the booster label expansion is a modest commercial event rather than a stock-moving binary.
How It Works
Bexsero is a vaccine that trains the immune system to recognize and fight Neisseria meningitidis serogroup B bacteria, which can cause meningitis and bloodstream infections. It contains four components: three lab-made proteins found on the surface of MenB bacteria (NadA, fHbp, NHBA) plus outer membrane vesicles from a MenB strain. When injected, the body produces antibodies against these components, providing protection if the person is later exposed to the bacteria.
Trial Status
Bexsero is an approved, marketed vaccine. A Phase IIIb study (Men-B-096) evaluating a single booster dose in healthy individuals aged 10-20 years supported the recent positive CHMP opinion for label expansion. Additional Phase II research is exploring cross-protection against gonorrhea. Multiple completed Phase 3 studies have evaluated Bexsero's safety and immunogenicity in infants and children.
The Two-Sided Case
Upcoming Catalysts
- European Commission decision on Bexsero booster label expansion for ages 10+ (expected within 1-2 months following November 13, 2026 CHMP positive opinion)
- Potential UK schedule expansion following the 2026 Kent meningococcal outbreak
- Ongoing research on Bexsero's cross-protection against gonorrhea (early-stage, no pivotal readout scheduled)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GSK plc 6-K GSK ·Originating report